Specifically, the healthcare unit will discontinue work on remote patient monitoring for heart failure and microneedles for drug delivery.
“We cannot do everything and have had to make some difficult choices,” said Verily’s CEO, Stephen Gillett, in an email to employees on Jan. 11.
In addition to the company scrapping some of its projects, Mr. Gillett said Jordi Parramon, the president of Verily’s devices businesses, would be leaving his role with the company.
Mr. Parramon has been with the company since its early days.
Despite the restructuring, Verily said it would continue to move forward with healthcare initiatives and is focusing on “operating in all areas of precision health,” and will continue “building the data and evidence backbone that closes the gap between research and care.”
